Medicine & Life Sciences
Acute Myeloid Leukemia
43%
Adoptive Immunotherapy
13%
Allogeneic Cells
86%
B-Cell Lymphoma
15%
B-Lymphocytes
16%
Beauty
13%
blinatumomab
13%
Bone Marrow
17%
Busulfan
45%
CD19 Antigens
13%
Cell Transplantation
67%
Cell- and Tissue-Based Therapy
39%
Chimeric Antigen Receptors
73%
Confidence Intervals
19%
Cyclophosphamide
21%
Cytogenetics
20%
Cytokine Release Syndrome
16%
Drug Therapy
18%
Fetal Blood
19%
fludarabine
40%
GATA2 Deficiency
21%
Graft vs Host Disease
46%
Haploidentical Transplantation
13%
Hematopoietic Stem Cell Transplantation
86%
Hematopoietic Stem Cells
13%
Homologous Transplantation
20%
Incidence
13%
Inotuzumab Ozogamicin
30%
Leukemia
15%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
13%
Melphalan
31%
Mortality
18%
Multiple Myeloma
41%
Myelodysplastic Syndromes
21%
Neoplasms
16%
Philadelphia Chromosome
27%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
100%
Progression-Free Survival
27%
Protein-Tyrosine Kinases
14%
Recurrence
30%
Residual Neoplasm
22%
Stem Cell Transplantation
69%
Stem Cells
24%
Survival
46%
T-Lymphocytes
46%
Therapeutics
17%
Tissue Donors
32%
Transplantation
41%
Transplants
66%
Unrelated Donors
29%